Recent Advances in Tumor Targeting via EPR Effect for Cancer Treatment
Open accessThe DOI matches its Crossref record; 172 of the 172 references it cites were found in a registry or an index.
Abstract
Cancer causes the second-highest rate of death world-wide. A major shortcoming inherent in most of anticancer drugs is their lack of tumor selectivity. Nanodrugs for cancer therapy administered intravenously escape renal clearance, are unable to penetrate through tight endothelial junctions of normal blood vessels and remain at a high level in plasma. Over time, the concentration of nanodrugs builds up in tumors due to the EPR effect, reaching several times higher than that of plasma due to the lack of lymphatic drainage. This review will address in detail the progress and prospects of tumor-targeting via EPR effect for cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 The two phenomena of extravasation and later diffusion and convection of the colloid in the extracellular matrix both result in enhanced permeation and retention of the nanoparticles [32].](https://figures.cochat.ai/paper-figures/887ab73c266443efbb3420cd636da176/recent-advances-in-tumor-targeting-via-epr-effect-for-cancer-treatment-figure-1.jpg)
![Figure 2 Common strategies utilizing the EPR effect [109].](https://figures.cochat.ai/paper-figures/89ba4512a64543b1a593fb62b3bf1725/recent-advances-in-tumor-targeting-via-epr-effect-for-cancer-treatment-figure-2.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In clinical settings, one of the main challenges for the delivery of macromolecules and nanomedicine to the cancer site is due to the heterogeneity of the EPR effect in solid tumors [20].”
From Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis (2023) · cites this paper as [20]
The cited source says what the claim attributes to it.
In the citing paper
“Several studies have demonstrated that only 0.1 to 0.2% of the injected dose is efficient against tumor cells and exhibits significant anticancer effects [20,123,161].”
From Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis (2023) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Cancer nanomedicine: progress, challenges and opportunities
Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873 · cited 1×
“The rapid tumor growth and improper development of blood vessels in murine tumors result in a much leakier vasculature as compared to human tumors that can lead to misinterpretation of the EPR effect [78].”
BackgroundDoxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792 · cited 1×
“The liposomal doxorubicin extravasated and accumulated intact in tumors with a leaky vasculature [79].”
BackgroundNanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233 · cited 1×
“To date, the FDA has approved many other liposomal formulations such as DaunoXome®, which contains daunorubicin, and Marquibo®, which contains vincristine sulfate for cancer therapy [123] as well as other types of nanoparticle including polymeric micelles containing paclitaxel (Genexol® PM), micelles built with PEG an…”
BackgroundFactors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699 · cited 1×
“The physicochemical properties of any external material for therapeutic or diagnostic purposes are important in drug delivery as they impact the way the host defense mechanisms clear them from the systemic circulation [57,58].”
BackgroundLiposome: classification, preparation, and applications
Akbarzadeh, A., Rezaei-Sadabady, R., Davaran, S., Joo, S. W., Zarghami, N., Hanifehpour, Y., Samiei, M., Kouhi, M., & Nejati-Koshki, K. (2013) · Nanoscale Research Letters · doi:10.1186/1556-276x-8-102 · Cited by 3,632
Delivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,180 · cited 3×
“They also depend on what stage the cancer is and the site it is located at [26,27,39].”
BackgroundNanoparticles in cancer therapy and diagnosis
Brigger, I., Dubernet, C., & Couvreur, P. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00044-3 · Cited by 3,039 · cited 1×
“These nanoparticles with a size below 50 nm are mostly used for the detection of brain tumors [140].”
REJMAN, J., OBERLE, V., ZUHORN, I. S., & HOEKSTRA, D. (2004) · Biochemical Journal · doi:10.1042/bj20031253 · Cited by 2,864 · cited 1×
“and spleen, but large enough to avoid kidney clearance [7,8].”
BackgroundBertrand, N., Wu, J., Xu, X., Kamaly, N., & Farokhzad, O. C. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.11.009 · Cited by 2,824
Research works printed but not linked: 1
- Dellian, 2000, Vascular permeability in a human tumour xenograft: Molecular charge dependence, Br. J. Cancer, 82, 1513
Cited by
Items 101–200 of 657
Harnessing nature: plant-derived nanocarriers for targeted drug delivery in cancer therapy
Alum, E. U., Nwuruku, O. A., Ugwu, O. P.-C., Uti, D. E., Alum, B. N., & Edwin, N. (2025) · Phytomedicine Plus · doi:10.1016/j.phyplu.2025.100828 · Cited by 35
A Review of Recent Advances in Magnetic Nanoparticle-Based Theranostics of Glioblastoma
Dhar, D., Ghosh, S., Das, S., & Chatterjee, J. (2022) · Nanomedicine · doi:10.2217/nnm-2021-0348 · Cited by 35
Hamdy, N. Μ., Eskander, G., & Basalious, E. B. (2022) · International Journal of Nanomedicine · doi:10.2147/ijn.s386037 · Cited by 35
“Nanocarriers (NCs) provide a golden solution for off-target side effects, through targeting mechanisms involving either passive targeting, where the nanoparticles (NPs) accumulate at the tumor site by the enhanced permeability and retention (EPR) effect that arises due to the leaky vasculature around the cancer cells…”
BackgroundCurrent trends in the development of liposomes for chemotherapeutic drug delivery
Kumbham, S., Ajjarapu, S., Ghosh, B., & Biswas, S. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104854 · Cited by 33
Nucleolin-Targeting AS1411 Aptamer-Conjugated Nanospheres for Targeted Treatment of Glioblastoma
Seo, K., Hwang, K., Nam, K. M., Kim, M. J., Shin, S., SONG, Y.-K., & Kim, C. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16040566 · Cited by 34
“A size of 40–200 nm may be suitable for nanoplatforms used for diagnosis and treatment and, even if the nanocarrier is smaller than 5 nm, it is easily excreted by the kidneys during the long-term circulation of the drug [81].”
BackgroundRecent advances in albumin nanoparticle-based cancer therapies
Shrestha, S., Shrestha, A., Kim, J., Thapa, R. K., & Kim, J. O. (2024) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-024-00687-6 · Cited by 33
“In cancer treatment, albumin nanoparticles provide passive target - ing based on the EPR effect effect where the nanoparticles escape from leaky angiogenic vessels and efficiently accu - mulate in tumor cells (Subhan et al. 2021 ).”
Chen, Y., Luo, X., Liu, Y., Zou, Y., Yang, S., Liu, C., & Zhao, Y. (2022) · International Journal of Nanomedicine · doi:10.2147/ijn.s376172 · Cited by 33
“Due to the incomplete tumor vascular basement membrane, enlarged vascular endothelial cell space (about 380–780 nm), and lack of lymphatic drainage, NBs can preferentially accumulate passively at tumor sites, which is called the enhanced permeability and retention (EPR) effect.(24) The PD-L1 mAb attached to the surfac…”
BackgroundAnwer, M. K., Ahmed, M. M., Aldawsari, M. F., Iqbal, M., & Kumar, V. (2022) · Pharmaceuticals · doi:10.3390/ph16010019 · Cited by 33
A review on tumor-targeting liposomes: Fabrication, mechanism and applications
Basak, S., Das, T. K., & Ganguly, S. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117460 · Cited by 37
Xia, Z., Zhang, C., Guo, C., Song, B., Hu, W., Cui, Y., Xue, Y., Xia, M., Xu, D., Zhang, S., et al. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.03.024 · Cited by 32
Changeable net charge on nanoparticles facilitates intratumor accumulation and penetration
Awaad, A., Takemoto, H., Iizuka, M., Ogi, K., Mochida, Y., Ranneh, A., Toyoda, M., Matsui, M., Nomoto, T., Honda, Y., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.04.025 · Cited by 34
Fukuta, T., & Kogure, K. (2022) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c21-00961 · Cited by 33
Starch-based carriers of paclitaxel: A systematic review of carriers, interactions, and mechanisms
Zhao, B., Gu, Z., Zhang, Y., Li, Z., Cheng, L., Li, C., & Hong, Y. (2022) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2022.119628 · Cited by 32
EPR Effect-Based Tumor Targeted Nanomedicine: A Promising Approach for Controlling Cancer
Fang, J. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12010095 · Cited by 31
“The discoverer of EPR effect, Professor Hiroshi Maeda, and his former students and colleagues summarized the history; principle; the progress and prospects of EPR effect-based tumor targeting strategies; and the application of nanomedicines [1,2,6,8], in which the concept of EPR effect is not only applied to the devel…”
BackgroundCell Membrane Biomimetic Nano-Delivery Systems for Cancer Therapy
Xia, Z., Mu, W., Yuan, S., Fu, S., Liu, Y., & Zhang, N. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15122770 · Cited by 34
Aryal, S., Park, S., Park, H., Park, C., Kim, W. C., Thakur, D., Won, Y., & Key, J. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s432839 · Cited by 33
Naser, S. S., Gupta, A. R., Choudhury, A., Yadav, A., Sinha, A., Kirti, A., Singh, D., Kujawska, M., Kaushik, N. K., Ghosh, A., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117372 · Cited by 32
Biological Nanocarriers in Cancer Therapy: Cutting Edge Innovations in Precision Drug Delivery
Ganpisetti, R., Giridharan, S., Jyothi, V. G. S. S., Narang, N., Basim, P., Dokmeci, M. R., Ermis, M., Rojekar, S. V., Gholap, A. D., & Kommineni, N. (2025) · Biomolecules · doi:10.3390/biom15060802 · Cited by 33
“The enhanced permeability and retention (EPR) effect, which permits the passive distribution and accumulation of liposomes into the tumor site, is caused by the combination of the leaky tumor vasculature and the restricted lymphatic drainage [35].”
Sahu, B. P., Baishya, R., Hatiboruah, J. L., Laloo, D., & Biswas, N. (2022) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-022-00583-x · Cited by 34
Targeted drug conjugate systems for ovarian cancer chemotherapy
Ogundipe, O. D., Olajubutu, O., & Adesina, S. K. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115151 · Cited by 48
Singh, D., & Kumar, A. (2025) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2025.1002355 · Cited by 37
Recent Advances in Zein-Based Nanocarriers for Precise Cancer Therapy
Huang, W., Yao, F., Tian, S., Liu, M., Liu, G., & Jiang, Y. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071820 · Cited by 32
“EPR effects depend on intrinsic tumor biological characteristics, nanocarrier size and cycle time [74].”
BackgroundNanotechnology Applications in Breast Cancer Immunotherapy
Wang, R., Kumar, P., Reda, M. M., Wallstrum, A., Crumrine, N. A., Ngamcherdtrakul, W., & Yantasee, W. (2023) · Small · doi:10.1002/smll.202308639 · Cited by 36
Nano-drug delivery strategies affecting cancer-associated fibroblasts to reduce tumor metastasis
Zou, L., Xian, P., Pu, Q., Song, Y., Ni, S., Chen, L., & Hu, K. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.02.040 · Cited by 29
“On the other hand, prolonging the circulation time of the NDDS is also a means to enhance their passive targeting via the EPR effect 190,192 .”
Davis, A. M., Morris, K. V., & Shevchenko, G. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.03.008 · Cited by 31
“In conclusion, we provide proof-of-concept work demonstrating the feasibility of targeting HSV-tk and Cas9 therapeutic cargo to hypoxic tumor cells using LNPs.”
BackgroundInfluentialZhang, Y., Zheng, D., Talaei, S., & Abasi, M. (2022) · Inorganic Chemistry Communications · doi:10.1016/j.inoche.2022.109423 · Cited by 29
Pt/DOX Nanomotors Enhance Penetration in the Deep Tumor by Positive Chemotaxis
Zhong, H., Zhang, Z., Zhou, Y., Wu, L., Peng, K., Lu, Y., Dai, Q., Bao, X., Xia, Y., Yang, Q., et al. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c09404 · Cited by 29
Dou, J., Mi, Y., Daneshmand, S., & Majd, M. H. (2022) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2022.104307 · Cited by 29
Wang, L., Jiang, W., Yang, M., Danzeng, Q., Liu, S., & Cui, M. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02275-z · Cited by 29
“It is called enhanced permeability and retention (EPR) effect [172].”
Liposomal nanostructures for Gemcitabine and Paclitaxel delivery in pancreatic cancer
Silli, E. K., Li, M., Shao, Y., Zhang, Y., Hou, G., Du, J., Liang, J., & Wang, Y. (2023) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2023.09.014 · Cited by 28
Nehal, N., Rohilla, A., Sartaj, A., Baboota, S., & Ali, J. (2024) · Journal of drug targeting · doi:10.1080/1061186x.2024.2356735 · Cited by 28
“…of this targeting strategy is based on animal tumour model yet its actual efficacy in humans is debateable [29]. in addition to this, the efficacy of the ePR is highly affected by the inherent features of the nanocarrier which includes its shape, charge, size and chemistry of the surface [30,31].”
Biodistribution Study of Niosomes in Tumor-Implanted BALB/C Mice Using Scintigraphic Imaging
de Silva, L. S., Fu, J., Htar, T. T., Kamal, W. H. B. W., Kasbollah, A., Muniyandy, S., & Chuah, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.778396 · Cited by 28
“The enhanced permeation and retention (EPR) effect was widely used in the development of nanocarriers for passive targeting (Subhan et al., 2021), where it involves the preferential accumulation of nanocarriers within solid tumors due to their leaky vessels that are formed as a result of uncontrolled angiogenesis (Bab…”
BackgroundInterventional nanotheranostics in hepatocellular carcinoma
Chavda, V. P., Balar, P. C., & Patel, S. B. (2023) · Nanotheranostics · doi:10.7150/ntno.80120 · Cited by 30
“Liposomes take advantage EPR effect (enhanced permeation and retention effect) of the leaking neo vasculature and passively concentrate near inflamed malignant cells, the EPR effect is caused by lack of adequate lymphatic outflow and increased permeability of tumor blood vessels [57-60].”
Carotenuto, P., Pecoraro, A., Brignola, C., Barbato, A., Franco, B., Longobardi, G., Conte, C., Quaglia, F., Russo, G., & Russo, A. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00876 · Cited by 28
“23 Natural products, like carotenoids, have shown the ability to enhance cancer cell response to cytotoxic drugs and may provide a safer choice to defeat MDR. 24,25 − 28 It has been proposed as a chemosensitizer affecting the expression of ABC transporters.”
InfluentialCritical Review in Designing Plant-Based Anticancer Nanoparticles against Hepatocellular Carcinoma
Basu, A., Namporn, T., & Ruenraroengsak, P. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15061611 · Cited by 29
Zhang, X., Li, L., Ren, Y., Li, M., & Tang, Y. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202413341 · Cited by 26
Patel, P. D., Vedarethinam, V., Korsah, M. A., Danquah, M. K., & Jeevanandam, J. (2024) · Applied Sciences · doi:10.3390/app14051809 · Cited by 28
Yang, C., Liu, K., Yao, C., Li, B., Juhong, A., Ullah, A. K. M. A., Bumpers, H. L., Qiu, Z., & Huang, X. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c01623 · Cited by 27
“21,22 To enhance NP accumulation in metastatic sites, cell surface receptors on tumor cells may be targeted.”
BackgroundNanoparticles as Physically- and Biochemically-Tuned Drug Formulations for Cancers Therapy
Foglizzo, V., & Marchiò, S. (2022) · Cancers · doi:10.3390/cancers14102473 · Cited by 26
Charles, O. O., Musa, M., Otuyalo, A. I., Gbayisomore, T. J., Zainab, O. D., George, S. D., Popoola, P. O., Olofin, O. O., Umunnam, K. F., Nneji, P. O., et al. (2023) · Discover Nano · doi:10.1186/s11671-023-03936-z · Cited by 29
“Drugs must be concentrated exclusively in tumors in order to reduce their systemic toxicity and increase their therapeutic efficacy; thus, the EPR effect is crucial [136].”
BackgroundRamayanam, N. R., Bukke, S. P. N., Moka, M. K., Dehingia, H., Bordoloi, A., Debbarma, R., Kudumula, P. R., Vuyyala, B., Prasad, P. D., & Catherine, A. (2025) · Discover Nano · doi:10.1186/s11671-025-04308-5 · Cited by 25
“Biomarker-based focused on and advanced nanoparticle designs play a vital position in enhancing the effectiveness of nanoparticle transport structures for TNBC [39].”
Nanoparticles derived from naturally occurring metal chelators for theranostic applications
Jung, W., Lee, D. Y., Moon, E., & Jon, S. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114620 · Cited by 25
Ji, H. B., Kim, C. R., Min, C. H., Han, J. H., Kim, S., Lee, C., & Choy, Y. B. (2023) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10477 · Cited by 25
“With the designated sizes of the NH2-MIL-101 (Fe) herein,(70) the formulation could be injected intravenously with a possible targeted delivery of therapeutic compounds.(71,72) In previous studies, ZIF-8 and MIL-100 MOFs were employed for”
MethodJustino, I. A., Marincek, A., Ferreira, I. R. S., do Amaral, R. L. F., Fontanezi, B. B., Mejía, J. A. A., Bastos, J. K., & Marcato, P. D. (2023) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgad030 · Cited by 25
Possible integration of artificial intelligence with photodynamic therapy and diagnosis: A review
Nkune, N. W., & Abrahamse, H. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.106210 · Cited by 29
Cardoso, B. D., Cardoso, V. F., Lanceros-Méndez, S., & Castanheira, E. M. S. (2022) · Biomedicines · doi:10.3390/biomedicines10051207 · Cited by 26
“It has been described that spherical particle with sizes between 50 and 200 nm can more easily avoid uptake by liver and spleen, and avoid kidney clearance exhibiting a greater tendency for long circulation [62].”
BackgroundRashidzadeh, H., Rezaei, S. J. T., Danafar, H., & Ramazani, A. (2022) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.103740 · Cited by 24
Bal‐Öztürk, A., Domingo, S., Yücel, O., Erol, T., Akgüner, Z. P., Darıcı, H., Alarçın, E., & Emik, S. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104195 · Cited by 29
Vikas, V., Mehata, A. K., Viswanadh, M. K., Malik, A. K., Setia, A., Kumari, P., Mahto, S. K., & Muthu, M. S. (2023) · Biomacromolecules · doi:10.1021/acs.biomac.3c00658 · Cited by 24
Tao, T., Rehman, S. U., Xu, S., Zhang, J., Xia, H., Guo, Z., Li, Z., Ma, K., & Wang, J. (2024) · Journal of Materials Chemistry B · doi:10.1039/d3tb02827e · Cited by 25
Suh, M., Park, J. Y., Ko, G. B., Kim, J. Y., Hwang, D. W., Rees, L., Conway, G. E., Doak, S. H., Kang, H., Lee, N., et al. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02699-8 · Cited by 25
“Additionally, extended circulation time may facilitate, enhanced permeability and retention (EPR) effect, selective accumulation in regions with compromised endothelial integrity, leading to superior differentiation between diseased and normal areas [47, 48].”
BackgroundGlioma nanotherapy: Unleashing the synergy of dual-loaded DIM and TMZ
Sarkar, S., Kumar, S., Saha, G., Basu, M., & Ghosh, M. K. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124697 · Cited by 25
Dadashi, H., Mashinchian, M., Karimian-Shaddel, A., Mohabbat, A., Vandghanooni, S., Eskandani, M., & Jahanban‐Esfahlan, R. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.138418 · Cited by 24
Kang, Y., Li, Z., Lu, F., Su, Z., Ji, X., & Zhang, S. (2021) · Nanoscale · doi:10.1039/d1nr07553e · Cited by 24
Zhou, Y., Camisasca, A., Gil, S. D., Bartkowski, M., Rochfort, K. D., Piletti, M., White, A., Krizsan, D., O'Connor, R. A., Quinn, S. J., et al. (2025) · Nanoscale · doi:10.1039/d4nr05186f · Cited by 23
Advances in the Mechanistic Understanding of Iron Oxide Nanoparticles’ Radiosensitizing Properties
Ternad, I., Penninckx, S., Lecomte, V., Vangijzegem, T., Conrard, L., Lucas, S., Heuskin, A., Michiels, C., Müller, R. N., Stanicki, D., et al. (2023) · Nanomaterials · doi:10.3390/nano13010201 · Cited by 23
“Although this effect remains controversial and is highly dependent on the tumor type, it can be hypothesized that a higher accumulation should be achieved for particles able to circulate for a long time in the bloodstream [25].”
BackgroundSinha, S., Tripathi, A. K., Pandey, A. K., Naik, P., Pandey, A., & Verma, V. S. (2024) · Biocatalysis and Agricultural Biotechnology · doi:10.1016/j.bcab.2024.103296 · Cited by 28
Cooley, M. B., Wegierak, D., & Exner, A. A. (2024) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1957 · Cited by 24
Bartusik‐Aebisher, D., Rogóż, K., & Aebisher, D. (2025) · Biomedicines · doi:10.3390/biomedicines13092160 · Cited by 23
“…bioavailability; (3 ) stimulus-dependent release—pH, reductase, and lysosomal enzymes allow for the release of agonists in target cells and minimize systemic effects; (4) surface modifications—cell-targeting ligands or PEGylation improve biodistribution and reduce immune agility [40,49–51].”
Lee, K. K., Lee, J., Lee, S. C., & Lee, C. (2022) · Theranostics · doi:10.7150/thno.77060 · Cited by 22
“However, for tumor accumulation via the enhanced permeability and retention effect, the nanoparticles should have a uniform shape and a suitable size of approximately 20–300 nm [30-32].”
BackgroundGonzález-Reyna, M. A., Molina, G. A., Juárez‐Moreno, K., Rodríguez, A., Esparza, R., & Estévez, M. (2023) · Biomaterials Advances · doi:10.1016/j.bioadv.2023.213561 · Cited by 22
Dong, Q., Wang, J., Liu, J., Zhang, L., Xu, Z., Kang, Y., & Xue, P. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202301453 · Cited by 22
Targeting the prostate tumor microenvironment by plant-derived natural products
Wu, J., Ji, H., Li, T., Guo, H., Xu, H., Zhu, J., Tian, J., Gao, M., Wang, X., & Zhang, A. (2023) · Cellular Signalling · doi:10.1016/j.cellsig.2023.111011 · Cited by 25
Innovative hybrid nanostructures: pioneering advances in modern therapy
Harun‐Ur‐Rashid, M., & Jahan, I. (2024) · Frontiers in Nanotechnology · doi:10.3389/fnano.2024.1458894 · Cited by 22
Khot, S. V., Mahajan, U., Jadhav, A., Vaishampayan, P., Bagul, U. S., Gadhave, D. G., Gorain, B., & Kokare, C. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.142861 · Cited by 22
Rodrigues, C. F., Fernandes, N. F., de Melo‐Diogo, D., Correia, I. J., & Moreira, A. F. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202201214 · Cited by 22
Rasel, M. S. I., Mohona, F. A., Akter, W., Kabir, S., Chowdhury, A. A., Chowdhury, J. A., Hassan, M. A., Mamun, A. A., Ghose, D. K., Ahmad, Z., et al. (2022) · Journal of Oncology · doi:10.1155/2022/9396760 · Cited by 27
Spiky Silver–Iron Oxide Nanohybrid for Effective Dual-Imaging and Synergistic Thermo-Chemotherapy
Moonshi, S. S., Vazquez‐Prada, K. X., Tang, J., van Holthe, N. J. W., Cowin, G., Wu, Y., Nguyen, D. H. T., Mckinnon, R., Bulmer, A. C., & Ta, H. T. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c04696 · Cited by 21
IDO-triggered swellable polymeric micelles for IDO inhibition and targeted cancer immunotherapy
Park, J., Nah, Y., & Kim, W. J. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.09.050 · Cited by 23
The role of magnetic nanoparticles in cancer management
Aladesuyi, O. A., & Oluwafemi, O. S. (2023) · Nano-Structures & Nano-Objects · doi:10.1016/j.nanoso.2023.101053 · Cited by 21
A review of design criteria for cancer-targeted, nanoparticle-based MRI contrast agents
Rahmati, S., & David, A. E. (2024) · Applied Materials Today · doi:10.1016/j.apmt.2024.102087 · Cited by 24
Maximiano, L. V., Corrêa, L. B., Gomes-da-Silva, N. C., da Costa, L. S., Silva, M. G. P. D., Chaves, A. V., Franco, M. L., Fechine, P. B. A., de Menezes, A. S., Santos‐Oliveira, R., et al. (2024) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2024.113931 · Cited by 21
Liu, D., Lü, N., Zang, F., Lu, M., Zhang, J., Zhao, Y., Wan, H., Wang, M., Li, Q., Wang, F., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c09387 · Cited by 21
Kamal, N. H., Heikal, L., & Abdallah, O. Y. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-024-01763-y · Cited by 20
“However, the formed vessels become chaotic and leaky [48].”
Rajankar, N., Kumar, A., & Gulbake, A. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.107050 · Cited by 21
Al-Jaber, H., Biswas, K. H., & Al-Mansoori, L. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1570712 · Cited by 23
“Nano-DDS with hydrodynamic diameters exceeding the renal clearance threshold remain in circulation longer, which allows them to extravasate through the leaky tumor vasculature (70, 71).”
Bao, Q., Zhang, Y., Liu, X., Yang, T., Hui, Y., Yang, M., & Mao, C. (2023) · Advanced Optical Materials · doi:10.1002/adom.202201482 · Cited by 20
Jarak, I., Santos, A. I., Pinto, A. H., Domingues, C., da Silva, I. S., Melo, R., Veiga, F., & Figueiras, A. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123456 · Cited by 21
Mathematical modeling of heat transfer in tissues with skin tumor during thermotherapy
Sherief, H. H., Zaky, M. F., Abbas, M. F., & Mahrous, S. A. (2024) · PLoS ONE · doi:10.1371/journal.pone.0298256 · Cited by 20
Theranostic nanoparticles for detection and treatment of pancreatic cancer
Agarwal, H., Bynum, R. C., Saleh, N., Harris, D., MacCuaig, W. M., Kim, V., Sanderson, E. J., Dennahy, I. S., Singh, R., Behkam, B., et al. (2024) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1983 · Cited by 21
Bhattacharya, S. (2022) · Journal of Experimental Nanoscience · doi:10.1080/17458080.2022.2060501 · Cited by 20
“Yuanyuan [60] developed erythrocyte membraneencased poly(d,l-lactide-co-glycolide) (PLGA) nanoplatforms for cancer immunotherapy [61, 62].”
BackgroundNanostructured lipid carriers in cancer therapy: Advances in passive and active targeting strategies
AlKhamach, D. M. H., Khan, S. A., Greish, K., Hassan, H. A. F. M., & Haider, M. A. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125736 · Cited by 20
Strategies for Pancreatic Cancer-Responsive Nanodrug Platforms Targeting Tumor Hypoxic Environments
Joo, K. S., Sym, S. J., Kim, K., & Khang, D. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s548825 · Cited by 22
“11,93 This approach does not require any special homing ligands.”
Yan, J., Ji, S., Chang, T., Yu, Z., Zhang, J., Hu, M., Xiu, C., & Huo, Q. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104433 · Cited by 19
Delivery of Chemotherapy Agents and Nucleic Acids with pH-Dependent Nanoparticles
Leng, Q., Imtiyaz, Z., Woodle, M. C., & Mixson, A. J. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15051482 · Cited by 19
“Tumor accumulation of the nanoparticles may also be increased by several factors, including the charge, size, and shape of the particle [21].”
BackgroundRecent Update on Nanocarrier(s) as the Targeted Therapy for Breast Cancer
Mukherjee, D., & Raikwar, S. (2024) · AAPS PharmSciTech · doi:10.1208/s12249-024-02867-x · Cited by 21
“This sequential approach allows enhanced and more selective drug delivery to tumour cells while minimizing off-target effects on healthy tissues [53].”
Longobardi, G., Moore, T. L., Conte, C., Ungaro, F., Satchi‐Fainaro, R., & Quaglia, F. (2024) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1990 · Cited by 21
Ndongwe, T., Zhou, A.-A., Ganga, N. P., Matawo, N., Sibanda, U., Chidziwa, T. V., Witika, B. A., Krause, R. W. M., Matlou, G. G., & Siwe‐Noundou, X. (2024) · Discover Nano · doi:10.1186/s11671-024-04089-3 · Cited by 19
“A number of nanoparticle formulations have demonstrated the ability to penetrate leaky vasculature associated with tumors and heterogeneity surrounding tumors [11].”
BackgroundRNA-loaded nanoparticles for the treatment of hematological cancers
Garbayo, E., Moukhtari, S. H. E., Rodríguez‐Nogales, C., Agirre, X., Rodríguez-Madoz, J. R., Rodríguez-Márquez, P., Prósper, F., Couvreur, P., & Blanco‐Prieto, M. J. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115448 · Cited by 20
Ghodeif, S. K., El-Fahla, N. A., Abdel-Rahman, M. A., & El‐Shenawy, N. S. (2025) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2025.03.005 · Cited by 25
In vivo nano-engineering T cells for CAR-T therapy
Shi, T., Li, Y., Deng, C., Ren, Q., Xu, C., & Zhong, Z. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114379 · Cited by 20
Caro, C., Guzzi, C., Moral‐Sánchez, I., Urbano‐Gámez, J. D., Beltrán, A. M., & García‐Martín, M. L. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202304044 · Cited by 19
Targeted immunotherapy and nanomedicine for rhabdomyosarcoma: The way of the future
Morel, V. J., Rössler, J. K., & Bernasconi, M. (2024) · Medicinal Research Reviews · doi:10.1002/med.22059 · Cited by 20
“65 Nevertheless, the number of preclinical and clinical studies on active drug delivery by nanoparticles has considerably increased in recent years, also including RMS, highlighting the benefits of identifying novel tumor targets.”
Zonouz, A. M., Taghavi, S., Nekooei, S., Abnous, K., Taghdisi, S. M., Ramezani, M., & Alibolandi, M. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124725 · Cited by 23
Alfreahat, I., Nsairat, H., Al‐Deeb, I., Al-Samydai, A. M., & Alshaer, W. (2025) · Technology in Cancer Research & Treatment · doi:10.1177/15330338241312561 · Cited by 19
“40,41 Particles with a diameter less than 200 nm are more ef fi cient but experiments with liposomes of different sizes suggest that the optimal size for escaping blood vessels and entering tumours is 400 nm. 42,43 Kong et al found that heat around 42 °C able to increase the pore cutoff size in…”
Jiang, S., Hao, B., Song, X., Jiang, Y., Guo, J., Wang, Y., Wang, Q., Wang, X., Xu, T., Wu, X., et al. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202403866 · Cited by 20
Non-Viral RNA Therapies for Non-Small Cell Lung Cancer and Their Corresponding Clinical Trials
Tiwade, P. B., Fung, V., VanKeulen‐Miller, R., Narasipura, E. A., Ma, Y., & Fenton, O. S. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00871 · Cited by 21
Jafari, S., Bakhshaei, A., Eskandani, M., & Molavi, O. (2022) · Assay and Drug Development Technologies · doi:10.1089/adt.2022.060 · Cited by 19
“36 Another aspect influencing the EPR effect is the drug’s release rate.”
Optimizing Cancer Treatment: A Comprehensive Review of Active and Passive Drug Delivery Strategies
Tarighi, P., Esfahani, S. M. M., Emamjomeh, A., Mirjalili, Z., & Mirzabeygi, P. (2025) · Iranian Biomedical Journal · doi:10.61882/ibj.4960 · Cited by 20
Gao, T., Fu, S., Quan, X., Sun, J., Jiang, M., & Li, J. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s566173 · Cited by 21
“226,227 The simplicity of designing such systems, coupled with their scalable production processes, has made them commercially attractive to pharmaceutical companies, as evidenced by all currently marketed anti-tumor nanomedicines belonging to this category.”
Metadata
- Authors
- Subhan, M. A., Yalamarty, S. S. K., Filipczak, N., Parveen, F., & Torchilin, V. P.
- Affiliations
- Shahjalal University of Science and Technology (BD)
- Northeastern University (US)
- Corresponding author
- Subhan, Md Abdus
- Torchilin, Vladimir P.
- ORCID
- Venue
- Journal of Personalized Medicine
- Publisher
- MDPI AG
- Published
- 2021-06-18
- Volume
- 11
- Issue
- 6
- Pages
- 571
- ISSN
- 2075-4426 (ISSN-L)
- PMC
- PMC8234032
- OpenAlex
- W3174294541
- Semantic Scholar
- 0e274cc5538c8ce64b42706c752e9cd357ce4ede
- Cited by
- 623
- References
- 172
- Citations by year
- 2026: 116 · 2025: 167 · 2024: 148 · 2023: 106 · 2022: 82 · 2021: 4
- FWCI
- 5.87
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Personalized Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Physical Sciences › Engineering › Biomedical Engineering › Ultrasound and Hyperthermia Applications
- Keywords
- enhanced permeability and retention effect, tumor targeting, cancer nanomedicine, nanotherapeutics, tumor selectivity, intravenous drug delivery, tumor microenvironment, lymphatic drainage
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.